{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-256538","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2023-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.295830+00:00","generated_at":"2026-06-09T23:26:48.139607+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Equillium presents pre-clinical data for oral EQ302 targeting IL-15/IL-21; analysts day held","bullets":["EQ302 is an orally deliverable multi-cytokine inhibitor targeting IL-15 and IL-21.","Pre-clinical data show hydrocarbon staples improve GI stability while retaining cytokine inhibition.","Oral EQ302 reduced IL-15-induced IFN-g transcription in mouse small intestine.","Potential utility for Celiac Disease and inflammatory bowel disease highlighted.","Analyst and investor day held October 16, 2023, with pipeline and platform update."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-256538","json":"https://secwatch.observer/filing/0001193125-23-256538.json","markdown":"https://secwatch.observer/filing/0001193125-23-256538.md","text":"https://secwatch.observer/filing/0001193125-23-256538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000119312523256538/0001193125-23-256538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000119312523256538/d500418d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T23:26:48.139607+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}